You are here: Home » News-CM » Companies » News
Business Standard

Zydus receives USFDA final approval for Desoximetasone Cream USP

Capital Market 

Zydus Cadila has received the final approval from the USFDA to market Desoximetasone Cream USP (US RLD Topicort Cream), 0.25%.

It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

Desoximetasone is a strong corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies and rash). It reduces the swelling, itching and redness that can occur in these types of conditions.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, October 01 2018. 15:17 IST